Literature DB >> 25663511

Report of a patient with chronic intractable autoimmune hemorrhaphilia due to anti-factor XIII/13 antibodies who died of hemorrhage after sustained clinical remission for 3 years.

Takeshi Kotake1, Masayoshi Souri, Koji Takada, Satoru Kosugi, Soichi Nakata, Akitada Ichinose.   

Abstract

Although the incidence of autoimmune hemorrhaphilia due to anti-Factor XIII (FXIII, not FVIII or FXII to avoid confusion) antibodies (AH13) or hemorrhagic "acquired FXIII deficiency due to anti-FXIII autoantibodies" was previously considered rare, it has been on the increase in the twenty-first century, at least in Japan. An 83-year-old woman with an unexplained hemorrhage was admitted to our hospital for intramuscular hematoma and severe anemia. Her FXIII activity was reduced to 10 % of normal; since FXIII inhibitors and anti-FXIII-A subunit autoantibodies were detected, she was definitively diagnosed with AH13. Despite developing cardiac tamponade due to pericardial hemorrhage, she clinically recovered from AH13 after hemostatic therapy with FXIII-concentrates and immunosuppressive treatment with rituximab and cyclophosphamide. However, her FXIII activity remained low and she died of hemorrhage 3.5 years after admission. AH13 patients should be monitored for a prolonged period, as this disease is very likely a chronic intractable hemorrhagic disorder.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663511     DOI: 10.1007/s12185-015-1754-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

Review 1.  Factor XIII: a coagulation factor with multiple plasmatic and cellular functions.

Authors:  László Muszbek; Zsuzsanna Bereczky; Zsuzsa Bagoly; István Komáromi; Éva Katona
Journal:  Physiol Rev       Date:  2011-07       Impact factor: 37.312

Review 2.  Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.

Authors:  Akitada Ichinose
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

Review 3.  Inhibitors of Factor XIII/13 in older patients.

Authors:  Akitada Ichinose
Journal:  Semin Thromb Hemost       Date:  2014-09-12       Impact factor: 4.180

4.  Reduced difference of α₂-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies.

Authors:  Akitada Ichinose; Masayoshi Souri
Journal:  Int J Hematol       Date:  2011-12-29       Impact factor: 2.490

5.  Clinical manifestations and management of life-threatening bleeding in the largest group of patients with severe factor XIII deficiency.

Authors:  Majid Naderi; Akbar Dorgalaleh; Shaban Alizadeh; Shadi Tabibian; Soudabeh Hosseini; Morteza Shamsizadeh; Taregh Bamedi
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490

6.  Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.

Authors:  M Souri; A Biswas; M Misawa; H Omura; A Ichinose
Journal:  Haemophilia       Date:  2013-11-29       Impact factor: 4.287

7.  Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis.

Authors:  Masatake Matsuoka; Tokifumi Majima; Tomohiro Onodera; Masahiro Ieko; Masayoshi Souri; Akitada Ichinose; Takashi Kurita; Yasuhiko Kasahara; Masahiro Inoue; Daisuke Takahashi
Journal:  Int J Hematol       Date:  2012-10-16       Impact factor: 2.490

8.  Male-specific cardiac pathologies in mice lacking either the A or B subunit of factor XIII.

Authors:  Masayoshi Souri; Shiori Koseki-Kuno; Naoki Takeda; Mitsunori Yamakawa; Yasuchika Takeishi; Jay L Degen; Akitada Ichinose
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

9.  Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency.

Authors:  Hideho Wada; Masayoshi Souri; Rui Matsumoto; Takashi Sugihara; Akitada Ichinose
Journal:  Thromb Haemost       Date:  2013-02-14       Impact factor: 5.249

10.  Diagnosis and classification of factor XIII deficiencies.

Authors:  H P Kohler; A Ichinose; R Seitz; R A S Ariens; L Muszbek
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

View more
  2 in total

1.  Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies.

Authors:  Minoru Kojima; Akitada Ichinose; Masayoshi Souri; Tsukasa Osaki; Hidetsugu Kawai; Jun Amaki; Hiroki Numata; Mitsuki Miyamoto; Daisuke Ogiya; Kosuke Tsuboi; Yoshiaki Ogawa; Soji Ozawa; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2015-11-30       Impact factor: 2.490

Review 2.  Measuring Factor XIII Inhibitors in Patients with Factor XIII Deficiency: A Case Report and Systematic Review of Current Practices in Japan.

Authors:  Shiho Amano; Kohei Oka; Yutaka Sato; Chiaki Sano; Ryuichi Ohta
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.